Tirzepatide Outperforms Semaglutide by 47% in Weight Loss - Middle East Business News and Information
In key secondary endpoints, tirzepatide was superior to semaglutide across all weight reduction targets and waist circumference reduction
Dubai, United Arab Emirates, May, 2025 – A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine.
For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2
In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm).
'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.'
Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ≥10% weight loss 81.6% 60.5% Achieved ≥15% weight loss 64.6% 40.1% Achieved ≥20% weight loss 48.4% 27.3% Achieved ≥25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm
'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.'
The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide.
About SURMOUNT-5:
SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, phase 3b trial evaluating the efficacy and safety of tirzepatide compared with semaglutide in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes. Participants in both treatment groups received counseling on a reduced-calorie diet and increased physical activity. The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). With tirzepatide, 89.3% received at least one dose of the 15 mg dose and with semaglutide 92.8% received at least one dose of the 2.4 mg dose. The primary objective of the study was to demonstrate tirzepatide's superiority in percent change from baseline in body weight at 72 weeks compared to semaglutide's.
About tirzepatide:
Tirzepatide is a once-weekly dual GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are ongoing.
About Lilly:
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
29-05-2025
- Mid East Info
UAE Hosts the First Intergovernmental Session of the IOC Sub-Commission for the Central Indian Ocean - Middle East Business News and Information
The UAE National Commission for Education, Culture, and Science, in collaboration with UNESCO's Intergovernmental Oceanographic Commission (IOC), hosted the First Intergovernmental Session of the IOC Sub-Commission for the Central Indian Ocean (IOCINDIO-1) recently, in Ras Al Khaimah. This milestone event reflects the UAE's long-standing commitment to strengthening international cooperation in scientific research and the protection of the marine environment. The meeting established a foundational framework for IOCINDIO's work, strengthening regional cooperation in ocean sciences and supporting progress toward key sustainable development goals. It brought together experts from international organizations specializing in ocean research and marine science. The meeting addressed several key themes, including the development of joint strategies to conserve marine ecosystems, the enhancement of research and technical capabilities among member states, and the expansion of knowledge in ocean monitoring and marine resource management. It also laid the groundwork for a collaborative framework to tackle shared environmental challenges, such as climate change and ocean pollution. IOCINDIO, a regional body under UNESCO's Intergovernmental Oceanographic Commission (IOC), aims to strengthen cooperation among Indian Ocean rim countries in the fields of scientific research and sustainable development. Underscoring the UAE's growing leadership on the global stage, the UAE was elected Chair of the Commission, represented by His Excellency Dr. Saif Mohammed Al Ghais, former Director General of the Environment Protection and Development Authority in Ras Al Khaimah. This prestigious appointment enables the UAE to play a central role in guiding the Commission's strategic direction, providing technical and logistical support, and advancing the coordination of regional scientific initiatives and events. His Excellency Sheikh Salem bin Khalid Al Qassimi, Minister of Culture and Chairman of the UAE National Commission for Education, Culture and Science, stated: 'The founding meeting of the Oceanographic Commission represents a significant milestone in the UAE's ongoing commitment to supporting UNESCO's programmes, particularly in the vital field of ocean sciences, which has become a global priority. At the National Commission, we remain dedicated to strengthening the UAE's presence on international scientific and cultural platforms through active collaboration with both local and global partners.' Her Excellency Dr. Amna bint Abdullah Al Dahak, Minister of Climate Change and the Environment said: 'We are proud to contribute to this important scientific event, which reflects the UAE's forward-looking vision to protect the marine environment and advance regional research in ocean sciences. Our collaboration with UNESCO and participating nations underscores our shared commitment to building a sustainable future for marine ecosystems.' His Excellency Raki Phillips, CEO of Ras Al Khaimah Tourism Development Authority, stated: 'The meeting aligns with Ras Al Khaimah's broader strategy to support environmental and scientific initiatives while reinforcing the Emirate's position as a global hub for sustainable events. We are proud to provide a welcoming and enabling environment that fosters meaningful scientific dialogue, with the potential to positively impact coastal communities in the UAE and across the region.'
Egypt Independent
18-05-2025
- Egypt Independent
FDA greenlights first blood test to help diagnose Alzheimer's disease in the US
The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer's disease, making the test the first to get signoff to aid in the early detection of the disease in the United States. The test, called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, is for adults 55 and older who are showing signs and symptoms of Alzheimer's disease, the FDA announced Friday. It works by measuring two proteins in blood plasma: pTau217 and beta-amyloid 1-42. A ratio of those proteins tends to correlate with the occurrence or absence of amyloid plaques in the brain, which are among the hallmarks of Alzheimer's disease. The test does not measure amyloid directly but can signal its presence. However, there remains no current single test to diagnose Alzheimer's disease. Doctors primarily rely on a variety of tools to diagnose the condition, which may include medical history, neurological exams, cognitive and functional evaluations, brain imaging, spinal fluid analysis and, more recently, blood tests. The FDA said the results of the newly cleared blood test must be assessed in conjunction with other clinical information from a patient. 'Alzheimer's disease impacts too many people, more than breast cancer and prostate cancer combined,' FDA Commissioner Dr. Martin Makary said in Friday's announcement. 'Knowing that 10% of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients.' According to the FDA, the new blood test – developed by the Pennsylvania-based biotechnology company Fujirebio Diagnostics Inc. – can help increase access to Alzheimer's disease detection and reduce reliance on positron emission tomography or PET scans, a type of imaging that can reveal amyloid plaques in the brain but can be expensive, costing thousands of dollars without insurance. The FDA said it reviewed clinical trial data on the new blood test, involving plasma samples collected from 499 adults who were cognitively impaired. The samples were evaluated using the blood test, and the results were compared with the results from patients' PET scans or separate testing using cerebrospinal fluid samples, such as from spinal taps. The data showed that 91.7% of adults with positive results using the blood test had the presence of amyloid plaques confirmed by their PET scan or cerebrospinal fluid test, and 97.3% of people with negative results had a negative amyloid PET scan or cerebrospinal fluid test result, according to the FDA. The agency added that the risks associated with the blood test are mainly the risk of a false positive or false negative test result. A 'new era' of Alzheimer's research Preventive neurologist Dr. Richard Isaacson, who established one of the first Alzheimer's prevention clinics in the United States, said he has been using this blood test for years for research and applauded the FDA clearance. 'It can provide better clarity into whether a person experiencing memory loss may have Alzheimer's disease. They can take this test as a screening test,' said Isaacson, director of research at the Institute for Neurodegenerative Diseases in Florida. Compared with costly PET scans or spinal taps, 'this is a much more simple screening test, with reasonable accuracy, to tell the physician that a person with cognitive decline has symptoms that are actually due to Alzheimer's disease.' But Isaacson warned that while the FDA clearance is 'an important step forward' for the field, more research is needed to help inform how blood test results should be interpreted and used to make clinical decisions. 'I think the next step as a field is, we need to advance education about what these tests mean and what they don't and who they should be used for,' he said. 'Because they mean different things in different people depending on their risk factors and whether or not they have symptoms. So we're still early.' Fujirebio Diagnostics designed the blood test to help detect Alzheimer's disease early, when interventions are more effective, president and CEO Monte Wiltse said in a news release last year , when the company filed its test with the FDA. 'An early and accurate diagnosis will also facilitate the development of new drug therapies, which are urgently needed as the prevalence of AD increases with a rapidly aging population globally,' Wiltse said. It's estimated that more than 2 in 5 people over the age of 55 in the United States – about 42% – will develop dementia in their later years. But in some cases, deposits of amyloid can start to accumulate in the brain decades before Alzheimer's symptoms begin. Early detection of these amyloid plaques could open the door for a person to take steps to slow the progression of disease, such as starting preventive treatment with medications. 'For too long Americans have struggled to get a simple and accurate diagnosis, with today's action by the FDA we are hopeful it will be easier for more individuals to receive an accurate diagnosis earlier,' Dr. Maria Carrillo, chief science officer and medical affairs lead at the Alzheimer's Association, said in a statement Friday. There are a variety of laboratory-developed tests on the market that can be used to detect blood-based biomarkers associated with Alzheimer's, according to the Alzheimer's Association, as well as experimental tests. But the Fujirebio Diagnostics test is the first one cleared by the FDA. 'Blood-based biomarkers are reshaping how we identify and understand Alzheimer's disease,' Carrillo said. 'At the same time, there are important questions for health care professionals to consider; in particular, who should be tested and when.' For now, the FDA's clearance 'marks a major milestone,' said Dr. Howard Fillit, co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. 'The ability to diagnose Alzheimer's earlier with a simple blood test, like we do for cholesterol, is a game changer, allowing more patients to receive treatment options that have the potential to significantly slow or even prevent the disease,' Fillit said in an email Friday. 'This is a clear example of the new era of Alzheimer's research where innovation, science and technology come together to develop more accessible, affordable and scalable tools that will pave the way for additional regulatory approvals of diagnostic tools.'
Mid East Info
13-05-2025
- Mid East Info
Tirzepatide Outperforms Semaglutide by 47% in Weight Loss - Middle East Business News and Information
Participants achieved an average weight loss of 20.2% with tirzepatide vs. 13.7% with semaglutide In key secondary endpoints, tirzepatide was superior to semaglutide across all weight reduction targets and waist circumference reduction Dubai, United Arab Emirates, May, 2025 – A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2 In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ≥10% weight loss 81.6% 60.5% Achieved ≥15% weight loss 64.6% 40.1% Achieved ≥20% weight loss 48.4% 27.3% Achieved ≥25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm 'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. About SURMOUNT-5: SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, phase 3b trial evaluating the efficacy and safety of tirzepatide compared with semaglutide in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes. Participants in both treatment groups received counseling on a reduced-calorie diet and increased physical activity. The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). With tirzepatide, 89.3% received at least one dose of the 15 mg dose and with semaglutide 92.8% received at least one dose of the 2.4 mg dose. The primary objective of the study was to demonstrate tirzepatide's superiority in percent change from baseline in body weight at 72 weeks compared to semaglutide's. About tirzepatide: Tirzepatide is a once-weekly dual GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are ongoing. About Lilly: Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
